Devyser has been awarded a tender for Devyser RHD, its product for non-invasive fetal RHD status in maternal plasma during pregnancy. The tender with Wales Blood Services covers fetal RHD testing in
"This is a strategic breakthrough in the
Devyser RHD is a highly sensitive CE-IVD labelled QPCR test to conduct accurate non-invasive screening for fetal RHD that helps clinicians avoid untargeted and unnecessary treatment.
The information was submitted for publication, through the agency of the contact persons below,
For more information, please contact:
Fredrik Alpsten, CEO
Email: fredrik.alpsten@devyser.com
Telephone: +46 70 667 31 06
Email: Theis.kipling@devyser.com
Telephone: +46 73 598 07 76
About Devyser
Devyser develops, manufactures and sells diagnostic solutions and analysis services to clinical laboratories in more than 50 countries. Our products are used for advanced genetic testing in the hereditary disease, oncology and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up. Devyser's products, and unique, patented solution requiring only one test tube, simplify genetic testing processes, improve sample throughput, minimize hands-on time and deliver rapid results. Our goal is for every patient to receive a correct diagnosis in the shortest possible time. Sustainability is a central part of our business and an important prerequisite for long term value creation.
Devyser was founded in 2004 and is based in
Devyser's shares are listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is
For more information, visit www.devyser.com.
https://news.cision.com/devyser-diagnostics-ab/r/devyser-wins-tender-for-non-invasive-fetal-rhd-testing-in-wales,c3888171
(c) 2023 Cision. All rights reserved., source